SHOX2 and lung carcinoma: Furthermore, a research in lung cancer showed that SHOX2 promotes tumorigenesis in lung cancer cells through the down-regulation of p53 and the activation of NF-κB, and leads to drug resistance in lung cancer cells through the aberrant regulation of cell cycle progression and the inhibition of apoptosis (Yang et al., 2015).